Skip to main content

Market Overview

LONZA GROUP AG LZAGY:OTCPK OTCPK
Companies may follow the International Reporting Standard, Alternative Reporting Standard, or are current in the SEC reporting obligations.

{{ portfolio.portfolio_name }}
You have no watchlists at this time, click "Manage watchlists" to create your first watchlist.
Manage watchlists

Sector: Health Care Industry: Life Sciences Tools & Services

56.46 -0.81 (-1.41%)

Data as of Apr 25, 2024

Prev. Close 57.27
Price Open 55.925
Volume 19,182
Day's Range 55.86 - 56.6
52 Wk Range 34.19 - 66
50 Day Moving Avg. 55.51
PE Ratio 58.828092
Shares Outstanding 721.17M
Market Cap 40.72B

Trade LZAGY stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B Vandana SinghWed, 20 Mar 2024 12:38:42 -0400
Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field Vandana SinghWed, 22 Jun 2022 06:39:57 -0400
Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses Vandana SinghWed, 02 Jun 2021 06:54:01 -0400
Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually Vandana SinghThu, 29 Apr 2021 08:26:47 -0400
aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810 Vandana SinghWed, 14 Apr 2021 09:42:44 -0400
Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza Vandana SinghFri, 12 Mar 2021 07:10:20 -0400
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2021 Benzinga InsightsTue, 23 Feb 2021 12:07:52 -0400
JP Morgan Upgrades Lonza Group to Overweight Benzinga NewsdeskTue, 23 Feb 2021 09:26:06 -0400
KeyBanc Initiates Coverage On Lonza Group with Sector Weight Rating Benzinga NewsdeskTue, 10 Nov 2020 05:14:11 -0400
Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development Shivdeep DhaliwalSun, 26 Jul 2020 22:38:07 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products PRNewswireSep 13, 2023
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate PRNewswireJan 27, 2022
Lonza Group AG to Host Earnings Call ACCESSWIREJan 27, 2021
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing PRNewswireAug 20, 2020
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy PRNewswireNov 05, 2019
Neptune to Expand Manufacturing Capability to Offer Cannabis Oil Capsules in Canada PRNewswireDec 21, 2018
Lonza Opens World's Largest Dedicated Cell and-Gene-Therapy Manufacturing Facility in Pearland, Greater Houston, TX (USA) PRNewswireApr 10, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Artisan International Fund Q1 2024 Commentary Seeking Alpha1 day ago
Artisan International Fund Q1 2024 Commentary Seeking Alpha1 day ago
Madison International Stock Fund Q1 2024 Investment Strategy Letter Seeking Alpha1 day ago
Madison International Stock Fund Q1 2024 Investment Strategy Letter Seeking Alpha1 day ago
Lonza: Acceleration In Mid-Term Sales Growth Seeking AlphaApr 04, 2024
Lonza: Acceleration In Mid-Term Sales Growth Seeking AlphaApr 04, 2024
Lonza appoints new CEO Seeking AlphaApr 02, 2024
Lonza appoints new CEO Seeking AlphaApr 02, 2024
Warning: LZAGY is at high risk of cutting its dividend Seeking AlphaMar 22, 2024
Warning: LZAGY is at high risk of cutting its dividend Seeking AlphaMar 22, 2024
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...